NXP800, an investigational cancer drug that inhibits the Heat Shock Factor-1 developed by the Institute of Cancer Research (ICR) in London, is going to enter the phase I clinical trials. The drug has shown promise in the pre-clinical stages by stopping cancer growth in culture and also regressed tumors in mice. The research will be funded by Nuvetics Pharma who has issued exclusive worldwide rights to develop and commercialize the drug, according to Globe Newswire. The oral drug acts as an inhibitor to the HSF1 pathway, an important regulator of cancer cell growth in various stages of malignancy. According to the research, the drug was able to block the growth of Ovarian Clear Cell Carcinoma and Endometroid Ovarian Cancer in Xenograft models. The company is planning to proceed with phase-1 of the trials in the fourth quarter and the research will be conducted with patients with advanced-stage solid tumors. Paul Workman FRS FMedSci, Chief Executive and President of The Institute of Cancer Research, London, the lead in the drugs discovery program, said, "We are delighted to have partnered NXP800 with the experienced team at Nuvectis following a highly creative successful drug discovery program here at The Institute of Cancer Research. We are confident that Nuvectis' management's demonstrated track record in drug development bodes well for the successful and rapid development of NXP800 and ultimately hope it becomes a much-needed new option that benefits patients with hard-to-treat cancers." Ron Bentsur, Co-Founder, Chairman, and Chief Executive Officer of Nuvectis, said, "We are excited to partner with the world-renowned ICR and CRT to advance the clinical development of NXP800. Building upon our team's proven track record of success in drug development, we intend to advance NXP800 through the clinical and regulatory process with an eye towards achieving our goal of helping people in their fight against cancer."
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.